Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.
We have identified a new role for the matrix enzyme lysyl oxidase-like-2 (LOXL2) in the creation and maintenance of the pathologic microenvironment of cancer and fibrotic disease. Our analysis of biopsies from human tumors and fibrotic lung and liver tissues revealed an increase in LOXL2 in disease-associated stroma and limited expression in healthy tissues. Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models. Inhibition of LOXL2 resulted in a marked reduction in activated fibroblasts, desmoplasia and endothelial cells, decreased production of growth factors and cytokines and decreased transforming growth factor-beta (TGF-beta) pathway signaling. AB0023 outperformed the small-molecule lysyl oxidase inhibitor beta-aminoproprionitrile. The efficacy and safety of LOXL2-specific AB0023 represents a new therapeutic approach with broad applicability in oncologic and fibrotic diseases.
Barry-Hamilton
Vivian
V
Arresto BioSciences, Palo Alto, California, USA.
Spangler
Rhyannon
R
Marshall
Derek
D
McCauley
Scott
S
Rodriguez
Hector M
HM
Oyasu
Miho
M
Mikels
Amanda
A
Vaysberg
Maria
M
Ghermazien
Haben
H
Wai
Carol
C
Garcia
Carlos A
CA
Velayo
Arleene C
AC
Jorgensen
Brett
B
Biermann
Donna
D
Tsai
Daniel
D
Green
Jennifer
J
Zaffryar-Eilot
Shelly
S
Holzer
Alison
A
Ogg
Scott
S
Thai
Dung
D
Neufeld
Gera
G
Van Vlasselaer
Peter
P
Smith
Victoria
V
D000594:Amino Acid Oxidoreductases / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D000629:Aminopropionitrile / Q000494:pharmacology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001943:Breast Neoplasms / Q000473:pathology; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D007783:Lactones / Q000494:pharmacology; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000473:pathology / Q000517:prevention & control; D011090:Polyenes / Q000494:pharmacology; D034741:RNA, Small Interfering / Q000235:genetics; D014158:Transcription, Genetic; D014162:Transfection; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D007783:Lactones; D011090:Polyenes; D034741:RNA, Small Interfering; D000629:Aminopropionitrile; D000594:Amino Acid Oxidoreductases; C119091:LOXL2 protein, human; C485601:Loxl2 protein, mouse
J Cell Biochem. 2007 Jul 1;101(4):887-907
17266048
Cancer Res. 2005 Oct 1;65(19):8887-95
16204060
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4315-30
16857807
Cancer Res. 1994 Dec 1;54(23):6083-6
7525053
Cancer Res. 2009 Jul 1;69(13):5292-3
19549886
Nat Rev Cancer. 2009 Feb;9(2):108-22
19165226
Cell. 2009 Nov 25;139(5):891-906
19931152
J Cell Biochem. 2003 Mar 1;88(4):660-72
12577300
Methods Mol Med. 2005;117:237-50
16118456
J Clin Pathol. 1988 Apr;41(4):467-70
3366935
Carcinogenesis. 2009 Oct;30(10):1660-9
19625348
Cancer Res. 2003 Apr 1;63(7):1657-66
12670920
Am J Respir Cell Mol Biol. 2007 Sep;37(3):291-9
17463394
Cell. 2005 May 6;121(3):335-48
15882617
J Biol Chem. 1979 Aug 25;254(16):7831-6
38246
Cancer Res. 2006 Jun 1;66(11):5816-27
16740721
Int J Cancer. 1988 May 15;41(5):707-12
2835323
Am J Respir Cell Mol Biol. 2008 Sep;39(3):324-36
18403781
Oncogene. 2004 Apr 12;23(16):2891-906
15077152
Clin Cancer Res. 2008 Oct 15;14(20):6405-13
18927279
N Engl J Med. 1999 Feb 11;340(6):430-6
9971867
Cancer. 2002 Dec 15;95(12):2546-54
12467069
EMBO J. 2005 Oct 5;24(19):3446-58
16096638
Int J Cancer. 2003 Oct 20;107(1):1-10
12925950
Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1147-54
17932231
Genes Chromosomes Cancer. 2007 Jul;46(7):644-55
17394133
Int J Cancer. 2009 Jul 15;125(2):318-27
19330836
Nature. 2004 Nov 18;432(7015):332-7
15549095
Cancer Res. 2002 Aug 1;62(15):4478-83
12154058
Cancer Res. 1999 Oct 1;59(19):5002-11
10519415
Am J Pathol. 2007 Jun;170(6):1807-16
17525249
CMAJ. 2004 Jul 20;171(2):153-60
15262886
J Cell Biol. 2007 Dec 17;179(6):1311-23
18086923
J Cell Physiol. 2001 Apr;187(1):117-23
11241356
Int J Biochem Cell Biol. 2008;40(3):362-82
17936056
Clin Cancer Res. 2001 Oct;7(10):3097-105
11595701
Panminerva Med. 1997 Sep;39(3):174-7
9360417
Int J Cancer. 2007 Aug 15;121(4):699-705
17534898
Cancer Res. 2008 Jan 15;68(2):561-70
18199553
J Appl Physiol (1985). 2005 May;98(5):1892-9
15829722
Nature. 2002 Dec 19-26;420(6917):860-7
12490959
J Cell Biochem. 2007 Aug 15;101(6):1338-54
17471532
Hepatology. 1994 Jul;20(1 Pt 1):15-20
8020885
Nature. 2006 Apr 27;440(7088):1222-6
16642001
Cancer Res. 2008 May 15;68(10):3835-43
18483268
Am J Respir Crit Care Med. 2009 Apr 1;179(7):588-94
19151190
EMBO J. 2008 Jun 18;27(12):1658-70
18497746
J Hepatol. 2005 Sep;43(3):499-507
16023247
Breast Cancer Res. 2005;7(4):R444-54
15987449
J Biol Chem. 1983 Apr 10;258(7):4331-8
6131892
J Biol Chem. 2010 Jul 2;285(27):20964-74
20439985
Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):600-8
9279246
Cancer Res. 2005 Jul 1;65(13):5864-71
15994964
EMBO J. 2004 Jul 21;23(14):2800-10
15229650
Hepatology. 2002 Jan;35(1):49-61
11786959
Clin Cancer Res. 2008 Oct 1;14(19):5995-6004
18829478
Cancer Res. 2000 Mar 1;60(5):1254-60
10728684
Nat Genet. 2008 May;40(5):650-5
18408720